Oncolytics’ Reolysin in new trial

The Children’s Oncology Group, in collaboration with the National Institutes of Health, intends to conduct a Phase 1 clinical trial of Oncolytics Biotech’s (TSX:ONC; NASDAQ:ONCY) Reolysin drug in combination with cyclophosphamide in pediatric patients aged three-to-21 with relapsed or refractory solid tumours. The primary objectives of the trial include estimating maximum tolerated dose, and defining [...]

Oncolytics posts positive interim data

Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY) has reported encouraging interim data from six patients in a 20-patient open-label Phase 1/2 cancer trial, testing Reolysin monotherapy on liver metastasis arising from primary colorectal cancer. Data from histological analysis presented by investigators at a medical conference in Spain showed a tumour response in four of six patients, two of [...]

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

Oncolytics ready for final step with Reolysin

After a 10-year journey, Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY ) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when [...]